The Board resolution dated February 09, 2023, the BOD of Imexpharm Corporation announced the following issues:
No
Content
2022
% plan in 2022
2021
% Growth
1
Total revenue
1,668.2
115.1%
1,290.8
29.2%
2
Net sales
1,643.7
1,266.6
29.8%
3
Profit after tax
301.8
109.7%
238.9
26.3%
1,620.0
-1.4%
305.0
1.1%
- Ms. Tran Thi Dao – Deputy Chairman of the BOD, General Director
- Mr. Nguyen Quoc Dinh – Chairman of the BOD, Deputy General Director.